A double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence

2009155 citationsJournal Article

Authors

James Shearer · National Centre for Clinical Research on Emerging Drugs

Shane Darke · National Centre for Clinical Research on Emerging Drugs

Craig Rodgers · Sydney Hospital

Tim Slade · National Centre for Clinical Research on Emerging Drugs

Ingrid van Beek · Sydney Hospital

John H. Lewis

Donna Brady · St Vincent's Hospital Sydney

Abstract

Modafinil demonstrated promise in reducing methamphetamine use in selected methamphetamine-dependent patients. The study findings support definitive trials of modafinil in larger multi-site trials.

Topics & Keywords

Neurotransmitter Receptor Influence on Behavior Forensic Toxicology and Drug Analysis Psychedelics and Drug Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Addiction

Volume 104, Issue 2, pp. 224-233

DOI: 10.1111/j.1360-0443.2008.02437.x

Field-Weighted Citation Impact: 5.65